Search
for
Sort by
Research 181–210 of 786
- Molecular crosstalk between lncRNA H19, miR-29a, and JAK2/STAT3 signaling in alopecia areata: a preliminary study
- Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Review of Promising Off-Label Use of Deucravacitinib
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Mechanisms of autophagy and their implications in dermatological disorders
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics
- Recent Advances in Drug Development for Hair Loss
- Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration
- Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review